trending Market Intelligence /marketintelligence/en/news-insights/trending/XZ9qFw_M54JpFxAtrEo1xg2 content esgSubNav
In This List

Bioblast seeking strategic alternatives to execute business objectives

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Bioblast seeking strategic alternatives to execute business objectives

Bio Blast Pharma Ltd. said it is exploring strategic business alternatives, including possible partnership and merger opportunities.

The clinical stage biotechnology company is considering options such as potential development and commercial partners for its investigational proprietary intravenous form of trehalose. Trehalose has been tested in humans with ocular pharyngeal muscular dystrophy and spinocerebellar ataxia type 3.

Bioblast has hired JSB-Partners to help the company execute its business development objectives.